麻豆传媒

Experts tackle myths, data bias, and game-changing outcomes of obesity drugs

Zenocutuzumab achieved response rates of 40% in pancreatic adenocarcinoma, 33% in advanced NSCLC

Selected highlights from the 2024 American College of Gastroenterology annual meeting

Benefits seen in patients with and without a genetic diagnosis

Alternating cycles of nab-paclitaxel-gemcitabine and gemcitabine alone boosted tolerability

Fourfold improvement in median PFS when added to standard-of-care systemic therapy

Health news and commentary gathered by 麻豆传媒 staff

Combination associated with favorable R0 resection and survival rates

Rate of major morbidity was non-inferior in the no-drain group compared with the drain group

PFS, adverse events also comparable with the ablative modalities after FOLFIRINOX chemotherapy

Shorter stays, faster surgeries, and less blood loss versus open surgery in Chinese study

Liposomal irinotecan-based regimen gets FDA greenlight for metastatic disease

Phase II study shows a 32% reduced risk of death compared with standard treatment

T-cell response linked to 86% reduced risk of relapse, death